
CLAIMS

1. A pharmaceutical composition for preventing and/or treating dyslipidemia, comprising:

a) a compound represented by the following general formula (1):

[Chemical formula 1]



(1)

, wherein R^1 and R^2, which may be identical or different, each represents a hydrogen atom, a methyl group, or an ethyl group; R^{3a}, R^{3b}, R^{4a} and R^{4b}, which may be identical or different, each represents a hydrogen atom, a halogen atom, a nitro group, a hydroxyl group, a C_{1-4} alkyl group, a trifluoromethyl group, a C_{1-4} alkoxy group, a C_{1-4} alkylcarbonyloxy group, a di-C_{1-4} alkylamino group, a C_{1-4} alkylsulfonyloxy group, a C_{1-4} alkylsulfonyl group, a C_{1-4} alkylsulfinyl group, or a C_{1-4} alkylthio group, or R^{3a} and R^{3b}, or R^{4a} and R^{4b} are joined to represent an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N-R^5 (wherein R^5 represents a hydrogen atom, a C_{1-4} alkyl group, a C_{1-4} alkylsulfonyl group, or a C_{1-4} alkyloxycarbonyl group); Y represents an oxygen atom, a $S(O)_l$ group (wherein l

~~represents 0, 1 or 2), a carbonyl group, a carbonylamino group,~~ an aminocarbonyl group, a sulfonylamino group, an aminosulfonyl group, or an NH group; Z represents CH, or N; n represents a number from 1 to 6; and m represents a number from 2 to 6, or a salt thereof, or a solvate of the compound, or a solvate of the salt of the compound; and

b) a cholesterol absorption inhibitor.

2. The pharmaceutical composition according to Claim 1, wherein the compound represented by the general formula (1) is (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid.

3. The pharmaceutical composition according to Claim 1 or 2, wherein the cholesterol absorption inhibitor is ezetimibe.

4. The pharmaceutical composition according to any one of Claims 1 to 3, wherein the dyslipidemia is a disease selected from the group consisting of mixed dyslipidemia, metabolic syndrome, dyslipidemia complicated by diabetes, hypo-HDL chloesterolemia ~~(hypo HDL-C-emia), and hypertriglyceridemia (hyper TG-emia).~~


~~5. The pharmaceutical composition according to any one of~~ Claims 1 to 4,

wherein a mass ratio of the compound represented by the general formula (1) to the cholesterol absorption inhibitor is 1 : 200 to 3 : 1.

6. A pharmaceutical composition for increasing HDL cholesterol (HDL-C), comprising:

a) a compound represented by the following general formula (1):

[Chemical formula 1]



(1)

, wherein R^1 and R^2, which may be identical or different, each represents a hydrogen atom, a methyl group, or an ethyl group; R^{3a}, R^{3b}, R^{4a} and R^{4b}, which may be identical or different, each represents a hydrogen atom, a halogen atom, a nitro group, a hydroxyl group, a C_{1-4} alkyl group, a trifluoromethyl group, a C_{1-4} alkoxy group, a C_{1-4} alkylcarbonyloxy group, a di-C_{1-4} ~~alkylamino group, a C_{1-4} alkylsulfonyloxy group, a C_{1-4}~~

~~alkylsulfonyl group, a C_{1-4} alkylsulfinyl group, or a C_{1-4}~~ alkylthio group, or R^{3a} and R^{3b}, or R^{4a} and R^{4b} are joined to represent an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N-R^5 (wherein R^5 represents a hydrogen atom, a C_{1-4} alkyl group, a C_{1-4} alkylsulfonyl group, or a C_{1-4} alkyloxycarbonyl group); Y represents an oxygen atom, a $S(O)_l$ group (wherein l represents 0, 1 or 2), a carbonyl group, a carbonylamino group, an aminocarbonyl group, a sulfonylamino group, an aminosulfonyl group, or an NH group; Z represents CH, or N; n represents a number from 1 to 6; and m represents a number from 2 to 6, or a salt thereof, or a solvate of the compound, or a solvate of the salt of the compound; and

b) a cholesterol absorption inhibitor.

7. The pharmaceutical composition according to Claim 6, wherein the compound represented by the general formula (1) is (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid.

8. The pharmaceutical composition according to Claim 6 or 7, wherein the cholesterol absorption inhibitor is ~~ezetimibe.~~

~~9. The pharmaceutical composition according to any one of~~ Claims 6 to 8,

wherein a disease requiring increase of HDL cholesterol (HDL-C) is a disease selected from the group consisting of mixed dyslipidemia, metabolic syndrome, dyslipidemia complicated by diabetes, hypo-HDL chloesterolemia (hypo HDL-C-emia), and hypertriglyceridemia (hyper TG-emia).

10. The pharmaceutical composition according to any one of Claims 6 to 9,

wherein a mass ratio of the compound represented by the general formula (1) to the cholesterol absorption inhibitor is ~~1 : 200 to 3 : 1.~~

CLAIMS

1. A pharmaceutical composition comprising:

a) (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, or a salt or solvate thereof; and

b) ezetimibe.

2. The pharmaceutical composition according to claim 1, wherein an amount ratio of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid to ezetimibe 1 : 200 to 3 : 1.